Smith & Nephew Plc Directorate Change (1955P)
20 Giugno 2022 - 8:00AM
UK Regulatory
TIDMSN.
RNS Number : 1955P
Smith & Nephew Plc
20 June 2022
20 June 2022
Smith+Nephew announces new Senior Independent Director
Smith & Nephew plc (LSE:SN, NYSE:SNN) announces that Robin
Freestone has decided to step down as Senior Independent Director
and as a Non-Executive Director of Smith & Nephew plc with
effect from 30 September 2022. Marc Owen, Non-Executive Director,
will be appointed as Senior Independent Director with effect from
the same date.
Mr Freestone was appointed as a Non-Executive Director in
September 2015 and subsequently appointed as Senior Independent
Director in April 2019. Mr Owen was appointed as a Non-Executive
Director in October 2017. In addition to his appointment as Senior
Independent Director, Mr Owen will continue in his role as Chair of
the Compliance & Culture Committee and as a member of the Audit
Committee and Nomination & Governance Committee. He will take
over from Mr Freestone in leading the search for a new Chair of the
company.
The Board would like to thank Mr Freestone for his commitment
and contribution to the Board and the Company and to congratulate
Mr Owen on his new appointment.
Enquiries
Investors
Andrew Swift +44 (0) 1923 477433
Smith+Nephew
Media
Charles Reynolds +44 (0) 1923 477314
Smith+Nephew
Susan Gilchrist / Ayesha Bharmal +44 (0) 20 7404 5959
Brunswick
About Smith+Nephew
Smith+Nephew is a portfolio medical technology business focused
on the repair, regeneration and replacement of soft and hard
tissue. We exist to restore people's bodies and their self-belief
by using technology to take the limits off living. We call this
purpose 'Life Unlimited'. Our 18,000 employees deliver this mission
every day, making a difference to patients' lives through the
excellence of our product portfolio, and the invention and
application of new technologies across our three global franchises
of Orthopaedics, Sports Medicine & ENT and Advanced Wound
Management.
Founded in Hull, UK, in 1856, we now operate in more than 100
countries, and generated annual sales of $5.2 billion in 2021.
Smith+Nephew is a constituent of the FTSE100 (LSE:SN, NYSE:SNN).
The terms 'Group' and 'Smith+Nephew' are used to refer to Smith
& Nephew plc and its consolidated subsidiaries, unless the
context requires otherwise.
For more information about Smith+Nephew, please visit
www.smith-nephew.com and follow us on Twitter , LinkedIn ,
Instagram or Facebook .
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
BOABSGDLSXBDGDL
(END) Dow Jones Newswires
June 20, 2022 02:00 ET (06:00 GMT)
Grafico Azioni Smith & Nephew (LSE:SN.)
Storico
Da Mar 2024 a Apr 2024
Grafico Azioni Smith & Nephew (LSE:SN.)
Storico
Da Apr 2023 a Apr 2024